Camidanlumab tesirine is a monoclonal antibody conjugated commercialized by ADC Therapeutics, with a leading Phase II program in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According to Globaldata, it is involved in 6 clinical trials, of which 2 were completed, 1 is ongoing, and 3 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Camidanlumab tesirine’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Camidanlumab tesirine is expected to reach an annual total of $25 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Camidanlumab tesirine Overview
Camidanlumab tesirine is under development for the treatment of CD25-expressing relapsed/refractory Hodgkin lymphoma, relapsed or refractory acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms, Non-Hodgkin lymphoma. The therapeutic candidate is administered as an intravenous infusion. ADCT-301 is an antibody drug conjugate composed of human IgG1 HuMax-TAC against CD25, stochastically conjugated through a dipeptide cleavable linker to a pyrrolobenzodiazepine (PBD) dimer warhead with a drug–antibody ratio of 2.3. It was also under development for prostate cancer, relapsed or refractory CD25-positive acute lymphocytic leukemia (ALL). It was under devlopment for the treatment of advanced solid tumors including head and neck squamous cell carcinoma, fallopian tube cancer, non-small cell lung cancer, gastric cancer, esophageal cancer, pancreas cancer, bladder cancer, renal cell carcinoma, melanoma, triple-negative breast cancer, ovarian cancer and colorectal cancer
ADC Therapeutics Overview
ADC Therapeutics is a biotechnology company that develops antibody-drug conjugates (ADCs) to treat hematologic malignancies and solid tumors. It offers Zynlonta, a CD-19-directed antibody for treatment of e B-cell lymphoma in adult patients. The company is provides Loncastuximab Tesirine (Lonca)and Camidanlumab Tesirine (Cami). ADC Therapeutics develops ADCT-602 drug for B-cell acute lymphoblastic leukemia, ADCT-601 targeting AXL in solid tumors, ADCT-901 against ovarian, triple-negative breast cancer and advanced solid tumors and ADCT-701 drug targeting DLK-1 in neuroblastoma, hepatocellular carcinoma, small cell lung cancer and myeloid leukemia. The company has operations in London, the UK and New Providence, and San Mateo, the US. ADC Therapeutics is headquartered in Lausanne, Switzerland.
The company reported revenues of (US Dollars) US$209.9 million for the fiscal year ended December 2022 (FY2022), compared to a revenue of US$33.9 million in FY2021. The operating loss of the company was US$163 million in FY2022, compared to an operating loss of US$261.7 million in FY2021. The net loss of the company was US$155.8 million in FY2022, compared to a net loss of US$230 million in FY2021.
For a complete picture of Camidanlumab tesirine’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.